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ABSTRACT 
 
 Migraine is a commonly-occurring primary headache disorder that can be extremely 
disabling. Despite its prevalence and impact, migraine remains under-recognized and under-
treated. The US Headache Consortium recommended validated screening measures as one way 
to improve headache diagnosis. Previous studies have sought to determine optimal symptom 
algorithms for differentiating migraine from other types of headache or to validate migraine 
screening measures, but few studies have attempted to do both.  
The current study attempted to statistically determine the most sensitive and specific 
symptoms for differentiating between migraine and other headache and validate the resulting 
symptom algorithm as a screening measure. Young adults who suffered from migraine (Group 1) 
and other headache (Group 2), based on their responses on a computerized diagnostic interview, 
served as participants. The total sample consisted of 1,829 participants (71.5% female; 74.4% 
white; mean age = 19.09 years [SD = 2.05]) who suffered from some type of headache, which 
was split randomly into experimental and validation samples. One hundred fifty-eight (8.6%) 
individuals met diagnostic criteria for migraine and 1,104 (60.3%) met for another type of 
headache. 
Headache duration of 4-72 hours (100%), severity ≥ 5 (91%), photophobia (90%), and 
phonophobia (90%) showed the highest sensitivity, while vomiting (98%), duration of 4-72 
hours (92%), nausea (89%), and headache-related disability (88%) showed the highest 
specificity. Symptoms that did not show either a positive likelihood ratio > 4.5 or negative 
likelihood ratio < 0.25 were eliminated. A backward stepwise logistic regression analysis was 
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performed on the remaining symptoms and resulted in an optimal model of duration of 4-72 
hours, nausea, photophobia, and phonophobia. ROC curve analyses showed that these items had 
an optimal operating point (OOP) of 3 out of 4 symptom endorsements, showing a sensitivity of 
94%, a specificity of 92%, and an AUC of 93% (+LR = 12.37, -LR = 0.06, PPV = 67%, NPV = 
99%).  
The current migraine screener performed much better than previous screening measures 
and has utility in identifying migraine among non-clinical and young adult samples. Potential 
uses of this screening measure are discussed, as are limitations of the current study and possible 
future directions. 
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CHAPTER 1 
 
INTRODUCTION 
Migraine Diagnosis and Burden 
 Migraine is a commonly-occurring primary headache disorder that can be extremely 
disabling and can have a major impact on many areas of an individual’s life. The diagnostic 
criteria for migraine are outlined in the 2004 International Headache Society’s (IHS) 
International Classification of Headache Disorders, Second Edition (ICHD-II; Headache 
Classification Subcommittee of the IHS, 2004). Migraine is defined as “a recurrent headache 
disorder manifesting in attacks lasting 4-72 hours” either untreated or unsuccessfully treated 
(IHS, 2004, p. 24). Typical characteristics of migraine include unilateral location, 
pulsating/throbbing quality, moderate or severe intensity, aggravation by or avoidance of routine 
physical activity, and association with nausea and/or vomiting and/or photophobia and 
phonophobia (IHS, 2004). Migraine can be divided into two major sub-types: migraine without 
aura (1.1) and migraine with aura (1.2). Though less common than migraine without aura, 
migraine with aura is characterized by neurological symptoms (i.e., aura) that are usually visual 
in nature and typically precede the other features of migraine. (See Appendix B for full criteria 
for migraine with and without aura).  
In the United States, migraine has a one-year prevalence of 17.1% for women and 5.6% 
for men (Lipton et al., 2007) and a lifetime prevalence of approximately 43% for women and 
18% for men (Stewart, Wood, Reed, Roy, & Lipton, 2008). Data from the World Health 
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Organization indicate that migraine is the third most common medical condition on the planet 
(Vos et al., 2012) and among the top 20 diseases worldwide that cause disability (WHO, 2013). 
In the US, migraine is responsible for approximately 113 million missed workdays annually, 
resulting in the loss of more than $13 billion each year (Stewart, Ricci, Chee, Morganstein, & 
Lipton, 2003). As such, migraine diagnosis and treatment research is of great importance in order 
to help alleviate this societal and individual burden. 
Poor Recognition and Treatment of Migraine 
 Although migraine is the leading reason for neurologist visits in the United States 
(Bekkelund & Albretsen, 2002; Carson, Ringbauer, MacKenzie, Warlow, & Sharpe, 2000), 
migraine remains under-recognized, under-diagnosed, and under-treated. Lipton, Amatniek, 
Ferrari, and Gross (1994) purported that one of the main barriers to the treatment of migraine 
was failure to provide an accurate diagnosis (thus precluding adequate treatment) for those who 
consult a physician. Approximately half of migraineurs never receive a diagnosis from a 
physician, and of those who do, one-third do not receive adequate treatment (Lipton, Stewart, & 
Simon, 1998; Lipton et al., 1994; Lipton, Diamond, Reed, Diamond, & Stewart, 2001; Lipton et 
al., 2002). In one Seattle-based study, primary care physicians correctly diagnosed less than 50% 
of migraineurs (Stang & VonKorff, 1994).  
Migraine remains under-diagnosed for many reasons, one of which may be because the 
migraine diagnostic criteria have had poor uptake by physicians due to the number of symptoms 
needing assessment (Martin, Penzien, Houle, Andrew, & Lofland, 2005). Although the best 
method of identifying migraine would be to assess each of the ICHD-II criteria using a structured 
diagnostic interview (Andrew, Penzien, Rains, Knowlton, & McAnulty, 1992), clinic settings 
often do not afford time for an interview of this type. Multiple medical problems are often 
	   3	  
assessed during a single primary care office visit, the average time of which is only 11- 20 
minutes in the United States (Carr-Hill, Jenkins-Clarke, Dixon, & Pringle, 1998; Mechanic et al., 
2001). Furthermore, the presence of multiple headache types (e.g., migraine and tension-type 
headache [TTH]) within an individual, which occurs in up to 51% of headache sufferers (Stang 
& Von Korff, 1994), makes it even less likely that migraine will be diagnosed (Lipton et al., 
1994). Another reason that migraine remains under-diagnosed is because many physicians are 
uncomfortable evaluating headache patients due to fears about overlooking the headache with a 
sinister cause (Detsky et al., 2006). Although headache due to a more serious neurological 
condition is only present in 1% of those with chronic headache, this concern can often lead to the 
overuse of neuroimaging and prolong visit times (Detsky et al., 2006). In addition to these 
barriers, migraine remains under-diagnosed also because most individuals with migraine do not 
seek treatment for their migraine, likely as a function of their gender (i.e., men tend to seek 
treatment less frequently than women), the severity of their headache, insurance status, and other 
economic factors (Lipton et al., 2003; Lipton et al., 2013). Migraine under-diagnosis has several 
negative consequences and can be improved through effective screening.  
Need for Effective Migraine Screening 
 Poor diagnostic recognition contributes to inadequate treatment and can contribute to 
higher headache-related disability and poorer health-related quality of life (Lipton et al., 2002). 
The US Headache Consortium recommended that one way to improve diagnosis of headache in 
primary care is the use of validated screening instruments (Dowson, Lipscombe, Sender, Rees, & 
Watson, 2002). A brief screening tool could help by increasing the speed and efficiency of 
migraine diagnosis, thus identifying individuals needing treatment and at high risk for other 
comorbidities (Lipton, Bigal, Amatniek, & Stewart, 2004). Migraine is often comorbid with 
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other disorders, such as depression, anxiety, epilepsy, and stroke (Lipton & Silberstein, 1994), 
and comorbidity is but one of the reasons that recognizing migraine early in its progression is of 
importance. Such is the primary goal of screening programs.  
 In addition, because migraine may be a progressive disease among some individuals 
(Bigal & Lipton, 2006), the aim of migraine screening is the early identification of individuals 
with migraine in order to treat current pain and prevent future pain and disability (Lipton et al., 
2004). Migraine-screening measures can be viewed as a low-cost, time-effective means of 
disease detection. Effective screening can reduce the direct (e.g., medical care costs) and the 
indirect costs of migraine (e.g., unemployment, underemployment, missed work) (Lipton & 
Silberstein, 2001; Solomon, 1997; Stewart, Lipton, & Simon, 1996; Von Korff, Stewart, Simon, 
& Lipton, 1998). For decades, researchers have attempted to develop brief algorithms and 
screening measures for more efficient migraine identification within primary care and neurology 
clinic settings.  
Statistics Used in Screening Instrument Literature 
 Statistics that are often reported in migraine identification studies of this type include 
sensitivity, specificity, positive and negative predictive values (PPV and NPV), and positive and 
negative likelihood ratios (+LR and –LR). Sensitivity (true positives) is the proportion of 
migraineurs correctly identified by the screening measure. If sensitivity is low, people with 
migraine will be missed. Specificity (true negatives) refers to people without migraine who are 
classified by the screener as negative for migraine. If specificity is low, people who do not have 
migraine will be classified as migraineurs. A sensitivity and specificity of 50% or 0.5 would 
mean the screening instrument is no better than chance at accurately classifying migraine status. 
In clinical practice, developers of screening instruments typically emphasize sensitivity over 
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specificity so as not to overlook individuals with the disease in question (Altman & Bland, 
1994a).  
 Predictive values, unlike sensitivity and specificity, are influenced by the prevalence of 
the disease in the population of interest. If examining a population with a high prevalence of 
migraine (such as a headache clinic), the probability is higher that those who screen positive for 
migraine will actually have migraine. Whereas sensitivity and specificity answer the question “If 
the patient does or does not have the disease, how likely is he/she to have a positive or negative 
test?,” the predictive values answer the question, “If the patient has a positive or negative test, 
how likely is he/she to have or not have the disease?” The PPV is the number of true-positives 
divided by the sum of all positive results (true-positives and false-positives combined), and the 
NPV is the number of true-negative results divided by the sum of all negative results (true-
negative and false-negative results combined). A high PPV indicates a strong likelihood that a 
person who screened positive has migraine, whereas a low PPV is usually found in samples with 
low prevalence of migraine. An ideal PPV and NPV would be 100% or 1.0 (Altman & Bland, 
1994b; Smith, Winkler, Fryback, 2000). 
 Likelihood ratios consider the pre-test probability of having a disease and, based on the 
results of the diagnostic test or screener, determine how much the probability of the disease 
increase or decreases. +LRs reflect how much the probability of disease increases if the 
diagnostic test is positive and -LRs reflect how much the probability of disease decreases if the 
diagnostic test is negative. An LR > 1 indicates an increased probability that the disorder is 
present, while an LR < 1 indicates a decreased probability that the disorder is present. An LR > 
10 reflects a large and often conclusive increase in the probability that the disorder is present, 5-
10 a moderate increase, 2-5 a small increase, 1-2 a minimal increase, and 1 reflects no change. 
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An LR of 0.5-1 reflects a minimal decrease in the probability that the disorder is present, 0.2-0.5 
a small decrease, 0.1-0.2 a moderate decrease, and < 0.1 reflects a large and often conclusive 
decrease in the probability that the disorder is present (Grimes & Schulz, 2005; Jaeschke, Guyatt, 
& Sackett, 1994).  
Symptom Algorithms Most Predictive of Migraine 
 Past attempts to improve the diagnosis of migraine have included statistical identification 
of symptoms most predictive of migraine in a given sample (algorithm studies), as well as the 
development of questionnaires that assess for migraine symptoms (screener-validation studies). 
Much research has been conducted on the subject but methods and findings are variable, and few 
studies have yielded brief migraine screening measures that have been subsequently employed in 
clinical practice.  
 In 2000, Smetana performed a meta-analysis of headache studies that attempted to 
determine which clinical features best distinguished migraine from TTH. This meta-analysis 
included seminal algorithm studies by Rasmussen, Jensen, and Olesen (1991), Henry et al. 
(1992), Michel et al. (1993), and Tom et al. (1994), among others. All studies included in this 
meta-analysis reported the most sensitive and specific migraine symptoms but did not attempt 
subsequently to validate these as part of a screening measure. (Studies attempting to validate 
screening measures are mentioned later in this literature review.) Smetana separated the findings 
of his meta-analysis into studies that used IHS diagnostic criteria and those that used other 
criteria before the development of the 1988 IHS criteria. Both types of studies produced similar 
findings: nausea showed the highest sensitivity (81%) and specificity (96%) for predicting 
migraine, followed by photophobia (79%, 86%), phonophobia (67%, 87%), aggravation by 
physical activity (81%, 78%), unilateral location (65%, 82%), and pulsating quality (73%, 75%). 
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Some of Smetana’s findings would be replicated in subsequent similar studies; however, findings 
from many symptom algorithm studies often differ from one another, likely as a function of 
differing methodologies, different samples employed, and different comparison groups. 
 In 2006, Detsky et al. (2006) conducted a systematic review of the migraine diagnostic 
literature employing both algorithm studies as well as screener-validation studies. They excluded 
more than half of identified relevant studies (n = 7) for the following reasons: 1) Two studies 
evaluated migraine symptom clusters that were very similar to the full IHS criteria and, therefore, 
were not “screening” measures (Rasmussen, 1991; Tom et al. 1994). (These studies were 
included and evaluated as part of the Smetana [2000] meta-analysis.) 2) One study included only 
migraine patients and therefore had no estimate of specificity because it lacked a control group 
(Cady, Borchert, Spalding, Hart, & Sheftell, 2004). 3) Two studies evaluated migraine symptom 
clusters that consisted of only two questions, one of which was “have you ever had migraine?” 
(Gervil, Ulrich, Olesen, & Russell, 1998; Maizels & Burchette, 2003). 4) One study sought to 
compare headache diary diagnoses to a clinical interview without presenting rates of individual 
migraine symptoms (Russell et al., 1992). 5) One study included no quantitative information 
regarding sensitivity or specificity of migraine symptoms (Merikangas, Dartigues, Whitaker, & 
Angst, 1994). As a result of these exclusions, Detsky and colleagues’ analysis included only one 
symptom study and three screener-validation studies, the latter of which are described in detail 
later (Lainez et al., 2005; Lipton et al., 2003; Pryse-Phillips et al., 2002). 
 The symptom study Detsky et al. (2006) reviewed was published by Michel et al. (1993). 
This study assessed for migraine symptoms in a French non-treatment-seeking headache sample. 
They sought to determine which migraine symptoms best differentiated migraine from “non-
migraine headache” (unspecified). They found that the most sensitive migraine symptoms in this 
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population were headache duration (74%), photophobia/phonophobia (66%), unilateral location 
(65%), and pulsating quality (64%). The most specific symptoms, on the other hand, were 
nausea/vomiting (93%), unilateral location (85%), pulsating quality (83%), disturbance of daily 
activities (76%; sometimes referred to as migraine-related disability and not a diagnostic 
criterion per se), and aggravation by physical activity (73%). Contrary to Smetana (2000), the 
authors of this review concluded that headache duration (4-72 hours) and disturbance of daily 
activity were among the most useful symptoms for discriminating between migraine and non-
migraine headache. Based on their review, Detsky et al. (2006) espoused that the mnemonic 
device of POUND (Pulsating, duration of 4-72 hOurs, Unilateral, Nausea, Disabling) should be 
used for differentiating migraine from non-migraine headache. If 4 of these 5 criteria were met, 
the +LR for definite or possible migraine was 24 [95% CI = 1.5-388], and if 3 of the 5 criteria 
were met, the +LR was 3.5 [1.3-9.2].  
 In a more recent study not included in either the Smetana (2000) or Detsky et al. (2006) 
review, Wang and colleagues (2008) sought to evaluate the diagnostic sensitivity of each ICHD-
II criterion within a Taiwanese neurology patient sample. They found that moderate to severe 
intensity (97%), nausea/vomiting (67%), and disability (65%) were the symptoms with the 
highest sensitivity, while photophobia (91%), nausea/vomiting (86%), phonophobia (79%), 
aggravation by physical activity (71%), and disability (70%) had the highest specificity in 
differentiating migraine, including “probable” episodic migraine (i.e., meeting all but one 
diagnostic criteria for migraine), from non-migraine headache (unspecified). They found that the 
optimal symptom cluster was nausea/vomiting, photophobia, and moderate to severe intensity 
(sensitivity = 73%, specificity = 82%, PPV = 91%, +LR = 4.06, -LR = .33). The second best 
model was nausea/vomiting, photophobia, and disability (sensitivity = 56%, specificity = 88%, 
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PPV = 92%, +LR = 4.67, -LR = 0.50), identical to the items that comprise the ID MigraineTM 
(Lipton et al., 2003). These findings differed from previously mentioned studies in that moderate 
to severe intensity was among the most sensitive and specific symptoms in differentiating 
migraine from non-migraine headache. 
 Other than Michel et al. (1993), a more recent study by Martin, Penzien, Houle, Andrew, 
and Lofland (2005) is the only other study published to date that has examined headache in non-
treatment-seeking sample. They sought to distinguish migraine (including probable migraine or 
“migrainous headache”) from non-migraine headache, such as TTH, cluster headache, 
medication overuse headache (MOH), chronic daily headache (CDH), and posttraumatic 
headache. In addition to 680 patients from headache and neurology clinics, Martin and 
colleagues also evaluated 784 community members and 99 college students. Data on the non-
clinical population were collected from 1989-1999. The college sample (M age = 27.8, 67% 
female) showed a migraine prevalence rate of 33%, with 8 headache days per month as the 
average. Within the college sample, nausea was the best indicator of migraine (+LR = 11.3, -LR 
= 0.35, PPV = 85%, NPV = 85%) followed by a combination of nausea, photophobia, and 
pulsating quality (+LR = 9.1, -LR = 0.3, PPV = 83%, NPV = 87%, AUC = 86%) and nausea, 
photophobia, and aggravation by physical activity (+LR = 22.3, -LR = 0.34, PPV = 92%, NPV = 
85%, AUC = 87%). Although this sample was not seeking treatment, similar to that of Michel et 
al. (1993), the findings differed in that unilateral location and headache duration were not 
important discriminators of migraine, thus showing that methodological and sample differences 
(such as differences in comparison groups) may influence differing conclusions. However, 
nausea consistently appears within the algorithm literature as an important discriminator of 
migraine. 
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Symptom-Based Screening Measures  
 As a supplement to research attempting to identify brief algorithms for migraine 
diagnosis, studies have also attempted to validate brief screening measures. In one of the first 
international attempts to employ a migraine screening instrument, Gervil, Ulrich, and Olesen 
(1998) administered four questions (process of selection unknown) by telephone to a large 
sample of Danish twins. The questions were: 1) “Have you ever had a migraine?” 2) “Have you 
ever had severe headache accompanied by nausea?” 3) “Have you ever had severe headache 
accompanied by hypersensitivity to sound and light?” 4) “Have you ever had visual disturbances 
lasting 5-60 minutes followed by headache?” Endorsement of all 4 items showed a sensitivity of 
85% and a specificity of 81% (PPV = 49%, NPV = 86%) in differentiating migraine from non-
migraine (TTH), but the authors did not report the psychometric properties of the individual 
items. One limitation of this study was that Questions 2 and 3 were not able to identify any more 
migraineurs than were identified by Question 1 alone. In addition, the fourth question (which 
assessed aura) incorrectly identified 62 migraineurs who were not classified as having aura by 
the ICHD criteria as well as 88 non-migraineurs; a total of 45% of individuals who responded to 
this question were incorrectly screened as having migraine with aura. As such, this questionnaire 
is not psychometrically sound and has not been employed in any other published studies to date. 
 In a more widely referenced study conducted outside the United States, Pryse-Phillips 
and colleagues (2002) assessed for migraine symptoms in a Canadian neurology sample (N = 
461). They attempted to identify symptoms that were best able to differentiate migraine from 
TTH. They found that the three symptoms of daily occurrence (reportedly used to rule-out 
migraine rather than diagnose migraine), unilateral location, and functional impairment 
(disability) best differentiated migraine from TTH. They subsequently developed a screening 
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measure from these three symptoms and administered it to 178 different neurology patients. The 
sensitivity of the three-item measure was 86%, and the specificity was 73% (PPV = 96%, NPV = 
38%). This study was unlike others in that the authors chose to include a screening item that 
functioned to rule-out migraine rather than identify migraine. In addition, this is one of the only 
studies that did not include nausea as an important differentiating symptom of migraine.  
 In one of the first and most well-known migraine screener studies conducted within the 
United States, Lipton and colleagues (2003) developed what is now the most widely-used 
screening measure for migraine, the ID MigraineTM. The ID MigraineTM is a three-item self-
report measure used to screen for migraine in a primary care setting. Lipton and colleagues first 
administered a 9-item measure of candidate symptoms to patients and retained those that were 
best at discriminating migraine from other types of headache (not specified). The most sensitive 
migraine symptoms were nausea (81%), photophobia (74%), and aura (74%). The most specific 
migraine symptoms were moderate to severe pain (94%), pulsating quality (87%), headache-
related disability (any one-day limitation in activities in the past 3 months; 87%), phonophobia 
(83%), photophobia (75%), and unilateral location (75%). The three final items retained for the 
ID MigraineTM (by way of backward logistic regression analysis) assess for symptoms of nausea, 
sensitivity to light, and headache-related disability, with only one symptom (i.e., disability) 
matching the results of Pryse-Phillips et al. (2002). Positive endorsement on two or more of the 
three items is considered a positive screen for migraine, having a sensitivity of 81% [77%-85%] 
and a specificity of 75% [64%-84%] (PPV = 93%, +LR = 3.2 [2.7-3.9], –LR = 0.25 [0.22-0.28]).  
The ID MigraineTM has been validated in samples in different countries (Brighina et al., 
2007; Gil-Gouveia & Martins, 2010) and within the US (Kim & Kim, 2006; Siva et al., 2008; Di 
Paolo, Di Nunno, Vanacore, & Bruti, 2009). Furthermore, two Turkish studies and one Brazilian 
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study have employed the ID MigraineTM to determine migraine prevalence among students 
(Bicakci et al., 2008; Domingues et al., 2011; Oztora et al., 2011) but did not attempt to validate 
the screener against a gold standard diagnosis. As such, the ID MigraineTM has never been 
validated within a student sample, and its diagnostic utility with non-treatment-seeking young 
adult headache sufferers remains undetermined.  
 In the same year, Maizels and Burchette (2003) sought to assess not only migraine, but 
also daily headache syndromes, medication overuse, and disability within a medical population. 
Their Brief Headache Screen (BHS) consists of seven questions, the diagnostic portion of which 
consists of three items: 1) “How often do you have headaches?” 2) “How often do you have 
severe headaches (disabling)?” 3) “How often do you take headache relievers or pain 
medicines?”. The respondent provides an answer to each item from the options: daily or near 
daily, 3-4 days/week, 2/week-2/month, 1/month or less, or almost never. Question 1 showed a 
sensitivity of 85% for identifying migraine when answered with anything other than daily or 
near daily or almost never and 98% when answered with anything other than almost never. The 
corresponding specificities were much lower (63% when answered almost never or daily or near 
daily and 29% when answered almost never). Maizels and Burchette did not report the sensitivity 
and specificity of Questions 1 and 2 combined because their goal was to differentiate episodic 
headache from chronic headache rather than differentiating migraine from other headache types. 
The BHS has limited use as a migraine screening measure, because it is lengthier than most 
others (7 items total), its format and scoring more complex, and its psychometric properties 
poorer than those of other validated measures. 
 Cady et al. (2004) attempted to validate a 3-Question Headache Screen in a large sample 
of adult migraineurs. Although the method of item selection is unknown, the questions were: 1) 
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“Do you have recurrent headaches that interfere with work, family, or social functions?” 2) 
“Does your headache last at least 4 hours?” 3) “Have you had new or different headaches in the 
past 6 months?” A diagnosis of migraine was suggested by a yes answer to questions 1 and 2 and 
a no answer to question 3. Migraineurs were recruited for this study using one of three methods: 
ICHD criteria (1988), physician’s clinical impression, or presence of recurring disabling 
headaches. The 3-item screener (with a positive response to questions 1 and 2 and a negative 
response to question 3) identified migraine in 78% of patients meeting ICHD-II criteria. Among 
the entire sample, Question 2 (duration over 4 hours) was endorsed by 94.7% of migraineurs. 
Although not part of the screening measure, the symptoms of nausea (86%), photophobia (90%), 
and phonophobia (74%) were commonly reported in the diagnostic recruitment portion of the 
study. The use of this instrument is limited as its specificity in differentiating migraine from non-
migraine headache is unknown and because its reported psychometric properties are lower than 
those of other similar instruments. In addition, although nausea and photophobia were commonly 
reported migraine symptoms, the authors did not indicate how these items performed (in 
differentiating migraine from other headache) nor explain why these items were not included in 
the screening measure.  
  Lainez and colleagues (2005) endeavored to identify migraine in a non-treatment-seeking 
sample that included individuals with migraine and those with other types of headache 
(predominantly TTH). They conducted their study in two stages. The initial version of the 
measure contained 15 questions based on the 1988 IHS diagnostic criteria. Of the original 15 
candidate questions, logistic regression analyses identified four optimal questions: 1) “Do you 
have frequent or intense headaches?” 2) “Do your headaches usually last more than 4 hours?” 3) 
“Do you usually suffer from nausea when you have a headache?” 4) “Does light or noise bother 
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you when you have a headache?” In the second stage, the authors added a fifth question related 
to headache disability and administered this final questionnaire (Migraine Screening 
Questionnaire; MS-Q) to 137 migraineurs. A positive screen on 4 of 5 questions showed a 
sensitivity of 92% [87%-99%], specificity of 81% [72%-91%], PPV of 83% [75%-91%], NPV of 
92% [85%-99%], +LR of 4.99 [3.04-8.19], and –LR of .09 [0.04-0.21]. The authors have since 
validated their questionnaire within a primary care setting (82% sensitivity, 97% specificity, PPV 
= 95%, NPV = 94%; Lainez et al., 2010). The MS-Q inquires about three additional migraine 
symptoms not in the ID Migraine (headache duration, intensity, and phonophobia) and is the 
only published questionnaire that was based from an algorithm and validated in a non-treatment-
seeking sample of migraineurs. As such, its findings have not been replicated. 
Need for the Current Study 
 In consideration of extant literature, the current study was needed for several reasons. 
First, methodological and comparison group differences between migraine studies (algorithm 
and screener-validation studies) limit replicability and comparability and are likely the main 
reasons for differing findings. Second, most of the previous literature has focused on 
discriminating migraine from other chronic headache syndromes likely to be represented in 
medical settings, but little research has been conducted in non-clinical samples that contain a 
high proportion of individuals with episodic TTH (ETTH), as well as individuals with chronic 
headache types. Lastly, although some studies have sought to create screening algorithms for 
identifying migraine and other studies have sought to validate migraine screening measures, 
rarely has the same study sought to both identify a brief algorithm for migraine and validate that 
algorithm as a screening measure. 
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One of the biggest methodological differences in the algorithm literature is that whereas 
some research reports on optimal “clusters” of symptoms for differentiating migraine 
(considering both the sensitivity and specificity of each item), other studies only provide 
information for those items that are the most sensitive versus those that are the most specific, 
without considering which items may constitute an optimal model for discriminating migraine 
from non-migraine headache. Additional limitations are that studies of screener validation often 
do not report how screener items were initially selected and comparison groups are not often 
described. With regard to meta-analyses and reviews, these varying methods within the 
culminating studies often are not taken into account before combining and reporting on their 
general findings. This likely is the main reason for disparate findings between studies, meta-
analyses, and reviews.  
The only migraine symptom that has shown to be an important discriminator of migraine 
across most studies is nausea, likely because individuals with other types of headache almost 
never experience nausea. Other symptoms of migraine, however, are less unique. For example, 
although photophobia, phonophobia, aggravation by physical activity, pulsating quality, and 
unilateral location are often present in migraine (and are, in some combination, required for a 
diagnosis of migraine), these symptoms can also be present in other headache syndromes.  
 With regard to sample differences, most research on migraine symptomatology to date 
has been conducted within headache clinics or primary care settings. Despite what is known 
about the large proportion of migraineurs who do not seek treatment or obtain an adequate 
diagnosis, few researchers have sought to identify the most relevant migraine symptoms within a 
non-treatment-seeking population. In addition, despite knowledge that incidence of migraine 
begins to rise most dramatically during young adulthood (Lipton, Bigal, Hamelsky, & Scher, 
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2008), that migraine prevalence among college students is approximately 25% (Bigal, Bigal, 
Betti, Bordini, & Speciali, 2001; McDermott, Peck, Walters, & Smitherman, 2013; Smitherman, 
McDermott, & Buchanan, 2011), and that the disability among these migraineurs is significant 
(Smitherman et al., 2011; Walters, Hamer, & Smitherman, 2014), only one study to date has 
attempted to identify the most predictive migraine symptomatology within a young adult sample 
(Martin et al., 2005). Notably, the student sample within the Martin et al. (2005) study was quite 
small (N = 99). 
The current study attempted to differentiate migraine from other headache types within a 
non-treatment-seeking sample of individuals. ETTH (headache characterized by mild to 
moderate bilateral pressure on both sides of the head) is the most common headache disorder in 
the world (Fumal, & Schoenen, 2008; Stovner et al., 2007; WHO, 2013) but, unless very 
frequent, is uncommon in clinical settings due to its relatively mild presentation. The inclusion of 
these individuals (in addition to those with more chronic headache, such as medication overuse 
headache [MOH], cluster headache, and chronic TTH) in the current study may result in a 
different symptom model than previous literature. 
 Finally, as mentioned above, few studies have both developed an algorithm for diagnosis 
and validated the algorithm as a screening measure. Although studies by Pryse-Phillips et al. 
(2002) and Lipton et al. (2003) attempted to do both, each study has shortcomings that limit the 
measures’ use in other populations and for purposes other than those originally intended. For 
example, the validation sample within the Pryse-Phillips study was relatively small (N = 128), 
and inclusion of a screening item that was used to rule-out rather than “rule-in” migraine 
complicates scoring and screening. In addition, their findings that left out nausea as an important 
discriminator of migraine call into question the study’s methodological integrity. Respondents 
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within the ID MigraineTM validation sample were pre-selected only if they were in an early 
symptomatic phase of migraine but had not yet presented to their physician, thus greatly limiting 
generalizability to the broader population. Although the ID MigraineTM measure has since been 
validated in other samples, it is unclear to what degree the uniqueness of the original validation 
sample affected the properties of the screening instrument. Further, the disability item included 
in both the screening measures developed by Pryse-Phillips et al. and Lipton et al. is not a 
diagnostic criterion of migraine and may also be present in those with other chronic headache 
types (Schwartz, Stewart, Simon, & Lipton, 1998). As such, specificity of the ID MigraineTM 
was found to be lower than desired (75%), as was test-retest reliability (kappa = 0.68). Due to 
these shortcomings of the two studies that have employed both algorithm development and 
screener-validation, more research is needed to develop a sensitive and specific brief screening 
measure for migraine diagnosis. 
  The current study first attempted to determine statistically the most sensitive and specific 
ICHD-II migraine symptoms for differentiating migraine from other headache types within a 
non-clinical population (i.e., algorithm development). As a supplement to the work of Martin et 
al. (2005), the current study then attempted to validate this algorithm of symptoms within a 
holdout sample from the larger overall sample (i.e., screener validation) and identify an optimal 
cut-off point for use. As previous literature suggests, nausea was hypothesized to be the strongest 
discriminator of migraine followed (in no particular order) by photophobia and/or phonophobia, 
and aggravation by physical activity. However, because findings vary regarding optimal 
discriminatory migraine symptoms, no a priori hypotheses were made about other candidate 
symptoms such as unilateral location, duration of 4-72 hours, or pulsating quality.  
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CHAPTER 2 
 
METHODS 
Participants 
 Participants were undergraduate students at the University of Mississippi who 
participated in exchange for modest psychology course credit. They completed an online battery 
of measures beginning in the fall of 2011 and ending in the winter of 2013. For preliminary 
analyses, those meeting ICHD-II diagnostic criteria for episodic migraine (with or without aura) 
or chronic migraine comprised the migraine group, while those with episodic, chronic, or 
probable TTH, cluster headache, posttraumatic headache, medication overuse headache, or those 
who complained of headache but could not be classified comprised the non-migraine group. For 
supplementary analyses, probable migraineurs (i.e., meeting all but one diagnostic criteria for 
migraine) were included as part of the migraine group.  
Measures 
 Structured Diagnostic Interview for Headache-Revised (SDIH-R). Included in the 
computerized battery of measures were questions from the computer-validated Structured 
Diagnostic Interview for Headache (SDIH; Andrew et al., 1992), which was modified to comport 
fully with current ICHD-II criteria. The computer-administered SDIH-R includes ten questions 
for diagnosing migraine without aura, one question assessing for headache frequency, two 
questions assessing for aura symptoms, five questions assessing for other headache disorders 
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(posttraumatic, cluster, and medication overuse headache), and a question about headache-
related disability (Appendix C).  
Procedures and Statistical Analyses 
 As mentioned above, the current study occurred in two phases. The dataset was randomly 
split by approximately 50%, with SDIH-R responses from the first half of participants (i.e., 
experimental sample) used for algorithm development and from the second half of participants 
(i.e., validation sample”) used for screener validation.  
 First, chi-square analyses and independent t-tests were performed to confirm that the 
experimental and validation samples did not significantly differ from one another on 
demographic variables, headache type, average headache days per month, or average headache 
severity. For algorithm development, two-by-two tables were constructed using each of the 
migraine symptoms (present vs. absent) and headache diagnoses (migraine vs. non-migraine). 
The sensitivity, specificity, predictive values, and likelihood ratios were calculated for each of 
the migraine symptoms. Receiver-operator characteristic (ROC) curves were then plotted for 
each of the one-variable migraine symptom models in order to determine which symptoms were 
most predictive of a migraine diagnosis, as provided by the area under the curve (AUC). The 
ROC curve plots reflected the extent to which the symptom in question differed in prevalence 
among people who have migraine versus another type of headache. Next, using the optimal 
model guidelines in Martin et al. (2005), symptoms were eliminated if they did not have +LRs > 
4.5 or –LRs < 0.25. A backward stepwise logistic regression analysis was then performed using 
the remaining variables to determine the optimal model for differentiating migraine from non-
migraine headache. The resulting model was used as the screening measure validated in the next 
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phase of the study. The optimal symptom model was also explored (supplementary to the main 
analyses) with the inclusion of probable migraineurs. 
 For screener validation, two-by-two tables were constructed using each possible cut-off 
point of the screening measure and headache diagnosis, from which sensitivity, specificity, LRs 
and PVs were calculated. An ROC curve then was plotted in order to determine the correlation of 
the screening measure with the gold standard diagnosis (AUC estimations) and the measure’s 
utility in differentiating migraine from other headache types as applied to the holdout validation 
sample. The ROC curve was used to analyze all possible cut-off points of the new screener and 
was used to determine the optimal operating point (OOP) of the screener (Halpern, Albert, 
Krieger, Metz, & Maidment, 1996). The OOP attempts to give the best trade-off between the 
costs of failing to detect positives and the costs of raising “false alarms.” The internal 
consistency (Cronbach’s alpha coefficient) of the new screening measure was also determined 
from the ROC curve analysis. Finally, the psychometric properties of the screening measure 
were examined as a function of gender and race. Although the screening measure was not 
designed to identify probable migraineurs, the utility of the screener was also examined within 
these individuals to supplement the main analyses.  
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CHAPTER 3 
 
RESULTS 
Data Analytic Assumptions 
 Histograms, Q-Q plots, and descriptive statistics data (i.e., skewness, kurtosis) were used 
to assess data analytic assumptions. The average number of headache days per month and 
average headache severity was normally distributed. No outliers were found on the variables of 
interest. 
Sample Comparison 
 The total sample consisted of 1,966 participants who responded positively to the initial 
question “Do you ever get headaches?” Excluding 137 with missing data, 1,829 were classified 
into 10 headache categories (see Appendix A Table 1) based on their responses to the SDIH-R. 
The sample of 1,829 was split randomly by approximately 50% to ensure equivalence between 
the experimental (n = 887) and validation (n = 942) samples. Non-significant chi-square tests 
(for gender, race [white vs. non-white], and headache category) and independent samples t-tests 
(for age, headache frequency, and headache severity) confirmed that the two samples did not 
differ significantly on any of these variables (see Appendix A Tables 1-3). 
Phase I: Experimental Sample and Algorithm Development 
 Characteristics of the Experimental Sample 
 Participants in the experimental sample were 70.8% female and 74.5% white, with a 
mean age of 19.05 (SD = 1.96). Sixty-nine (7.8%) participants met ICHD-II diagnostic criteria 
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for migraine (chronic or episodic with or without aura), thus comprising the migraine group, and 
552 (62.2%) met diagnostic criteria for another type of headache, thus comprising the non-
migraine group. In addition, 266 (30.0%) met criteria for probable migraine. They were excluded 
from primary analyses in order to comport strictly with the ICHD-II diagnostic criteria for 
migraine, but they were included as part of the migraine group in supplementary analyses. 
 Episodic migraineurs with aura (n = 17) and without aura (n = 29) within the 
experimental sample reported an average of 6.94 (SD = 3.09) and 7.76 (SD = 5.60) headache 
days per month, respectively, while chronic migraineurs (n = 23) reported an average of 18.61 
(SD = 4.07) headache days per month. The average number of headache days per month reported 
by all migraineurs (11.17 [SD = 6.98]) was significantly higher than the average number of 
headache days per month reported by individuals with non-migraine headache (5.29 [SD = 4.72]; 
t(619) = -9.20, p < .001).  Average headache severity was not significantly different between 
chronic (M = 6.13, SD = 1.06) and episodic (M = 6.37, SD = 1.60) migraineurs, t(67) = 0.65, p = 
.518; however, as expected migraineurs reported significantly higher pain severity (6.29 [SD = 
1.44]) than did individuals with non-migraine headache (3.88 [SD = 1.62]; t(619) = -11.76, p < 
.001). 
 Algorithm Development 
 Within the experimental sample, the performance of each migraine symptom was 
compared to the gold standard diagnosis of migraine as acquired via the SDIH-R. Two-by-two 
tables were created showing the number of migraineurs and non-migraineurs endorsing each 
symptom (see Appendix A Table 4), from which sensitivity, specificity, positive and negative 
likelihood ratios, and positive and negative predictive values were calculated (see Appendix A 
Table 5). Headache duration of 4-72 hours showed the highest sensitivity (100%), followed by 
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severity ≥ 5  (91%), photophobia (90%), and phonophobia (90%). In contrast, vomiting showed 
the highest specificity (98%), followed by duration of 4-72 hours (92%), nausea (89%), and 
disability (defined as headaches interfering with work, school, or personal life; 88%).  
ROC curves were then plotted in order to determine which symptoms were best at 
differentiating migraine from other headache types (see Appendix A Table 5). Duration of 4-72 
hours had the largest AUC (96%), followed by photophobia (78%), severity ≥ 5 (78%), and 
nausea (77%). Next, unilateral location, pulsing quality, and worsening by physical activity were 
ruled-out as part of the optimal model as they did not have an +LR > 4.5 or –LR < 0.25. The 
remaining 7 symptoms (i.e., duration of 4-72 hours, severity ≥ 5, nausea, vomiting, photophobia, 
phonophobia, and disability) were entered in a backward stepwise logistic regression analysis to 
determine the optimal model for distinguishing migraine from other headache types. The 
retained optimal model consisted of duration of 4-72 hours (B = 21.08), nausea (B = 1.18), 
photophobia (B = 1.87), and phonophobia (B = 1.54). This model was validated as a screening 
measure in the next phase of the study. 
 Using the same procedures delineated above, analyses were repeated when including 
probable migraineurs as part of the migraine sample (see Appendix A Table 6). When including 
those with probable migraine in the migraine group, duration of 4-72 hours no longer displayed 
the greatest sensitivity. Instead, photophobia showed the highest sensitivity (90%), followed by 
phonophobia (89%), pulsing quality (77%), and severity ≥ 5 (73%). AUCs were also different 
from the original model; photophobia showed the highest AUC (78%), followed by phonophobia 
(72%), nausea (70%), and severity ≥ 5 (69%) (see Appendix A Table 7). Optimal likelihood 
ratios when including those with probable migraine were found for nausea (B = 1.77) and 
photophobia (B = 2.73). Because this was a supplementary aim of the present study, validation 
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was not attempted on this 2-symptom model. Instead, the validity of the original 4-symptom 
screener was explored within probable migraine sufferers in subsequent validation analyses. 
Phase II: Validation Sample and Screener Validation  
 Characteristics of the Validation Sample 
 Participants in the validation sample were 72.2% female and 74.2% white, with a mean 
age of 19.12 (SD = 2.13). Eighty-nine (9.4%) participants met ICHD-II diagnostic criteria for 
migraine (chronic or episodic with or without aura), thus comprising the migraine group, and 552 
(58.6%) met diagnostic criteria for another type of headache, thus making up the non-migraine 
group. In addition, 301 (32.0%) met criteria for probable migraine and were explored as part of 
the migraine group in supplementary analyses.  
 Episodic migraineurs with aura (n = 26) and without aura (n = 45) within the validation 
sample reported an average of 6.65 (SD = 3.43) and 6.29 (SD = 3.28) headache days per month, 
respectively, while chronic migraineurs (n = 18) reported an average of 18.44 (SD = 4.66) 
headache days per month. The average number of headache days per month reported by all 
migraineurs (8.85 [SD = 6.04]) was significantly higher than the average number of headache 
days per month reported by individuals with non-migraine headache (5.46 [SD = 4.87]; t(639) = -
5.89, p < .001). Average headache severity was not significantly different between chronic (M = 
6.78, SD = 1.35) and episodic (M = 5.99, SD = 1.66) migraineurs, t(87) = -1.87, p = .065; 
however, as expected migraineurs reported significantly higher pain severity (6.15 [SD = 1.63]) 
than did individuals with non-migraine headache (3.81 [SD = 1.64]; t(638) = -12.49, p < .001). 
Screener Validation 
 To validate the prior 4-factor model as a screening algorithm in the holdout validation 
sample, two-by-two tables were created for each possible cut-off point of the screener (see 
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Appendix A Table 8), from which sensitivity, specificity, positive and negative likelihood ratios, 
and positive and negative predictive values were calculated (see Appendix A Table 9). The OOP 
for the screener was positively endorsing 3 out of 4 items. This OOP had a sensitivity of 94% 
and a specificity of 92% (+LR = 12.37, -LR = .06, PPV 67%, NPV 99%). ROC curve analyses 
were used to determine the correlation of each cut-off point with the gold standard diagnosis of 
migraine (see Appendix A Table 9). The AUC of positively endorsing 1 or more items was 69% 
[95% CI: 65-74%], of 2 or more items was 87% [85-90%], of 3 or more items was 93% [90-
96%], and of all 4 items was 78% [72-85%]. When including probable migraineurs, the 4-item 
screener showed an OOP of responding positively to 2 or more items (AUC = 87% [84-89%]; 
see Appendix A Table 11). All items in the screening algorithm were significantly intercorrelated 
(rs from .18 to .51, ps ≤ .01) and were highly correlated with the OOP of the screener (rs from 
.42 to .71, ps ≤ .01). The internal consistency (Cronbach’s alpha) for this measure was .60.  
Group Differences in Screener Performance 
 As shown in Appendix A Table 12, the screening measure performed better statistically 
among men than in women at all 4 cut-off points; however this statistically significant difference 
is almost certainly a function of the large sample size and not clinically meaningful, as the AUC 
at the OOP of the screener was 94% among men versus 93% among women) The screener 
performed equally well among white and non-white individuals (see Appendix A Table 13). 
 
	   26	  
CHAPTER 4 
 
DISCUSSION 
 The current study sought to identify an algorithm for migraine diagnosis and to validate 
this algorithm as a screening instrument in a non-treatment-seeking sample of young adults. 
Previous studies within this area of study rarely have attempted to accomplish both these goals 
within the same sample, and prior research of this type varies widely with regard to 
methodology, comparison groups, and results. Duration of 4-72 hours, nausea, photophobia, and 
phonophobia composed the optimal model for differentiating migraine from non-migraine 
headache and showed high sensitivity, specificity, and correlation with the gold standard 
diagnosis at the OOP. The screening measure was not as well able to differentiate migraine from 
non-migraine headache when including probable migraineurs but still proved useful at 
distinguishing migraine (when including probable migraineurs) at a different OOP.  
 The screening measure had very strong clinical utility among men and women and 
among white and non-white individuals at its optimal operating point. Although the internal 
consistency (Cronbach’s alpha) for this measure was poor, this finding is not surprising given the 
few number of items retained and their lack of redundancy; this does not preclude its use given 
the purpose of the measure (Tavakol & Dennick, 2011). In general, the current findings 
confirmed the a priori hypotheses and resemble findings of extant literature. 
Migraine Prevalence 
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 The prevalence rate of migraine within the current study (8.6%) was lower than that 
suggested by previous literature conducted within the same population (Smitherman et al., 2011; 
Walters et al., 2014). These studies found that approximately one quarter of college students met 
criteria for episodic migraine. However, these studies extended migraine duration to two hours 
instead of four, and thus included probable migraineurs. When including probable migraineurs in 
the current sample, prevalence rises to approximately 40%, which more closely matches the 
findings of Martin and colleagues (2005), who found a prevalence rate of 33% (including 
probable migraineurs) in a college sample. Another possible explanation for the disparity in 
prevalence could be the difference in methodology used for diagnosing headache. For example, 
Smitherman et al. and Walters et al. employed the same computer-administered diagnostic 
interview as the current study, but the former studies administered the interview in-person, rather 
than online. This in-person method allowed for more clinical judgment regarding diagnosis, as 
well as the ability for clarification and follow-up questions, whereas the computer-administered 
version of the diagnostic criteria in the current study did not allow for this type of follow-up and 
was more rigid in diagnosis. 
Comparison to previous findings 
 In the current study, duration of 4-72 hours, severity ≥ 5, photophobia, and phonophobia 
showed the highest sensitivity, while vomiting, duration of 4-72 hours, nausea, and disability 
showed the highest specificity. Ultimately, the 10 migraine symptoms were effectively reduced 
to a 4-item screener including the symptoms of duration of 4-72 hours, nausea, photophobia, and 
phonophobia. These findings are generally similar to those of most previous studies, but this is 
the first study to find this unique combination of duration of 4-72 hours, nausea, photophobia, 
and phonophobia as an effective screener for migraine. The meta-analysis by Smetana (2000); 
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the review by Detsky et al. (2006); and studies by Michel et al. (1993), Wang et al. (2008), 
Martin et al. (2005), Lipton et al. (2003), Cady et al. (2004), and Lainez et al. (2005) all found 
that nausea and photophobia were among the most sensitive and specific symptoms for 
distinguishing migraine from other headache types. In addition, five of these studies also found 
phonophobia to be one of the most sensitive and specific symptoms for identifying migraine 
(Cady et al., 2004; Lainez et al., 2005; Michel et al., 1993; Smetana, 2000; Wang et al., 2008), 
but it was included as part of the optimal model in only one of these studies (Lainez et al., 2005).  
 The main difference in findings between the current study and previous literature is that 
of duration being an important differentiator of migraine in combination with these other 
symptoms. While Detsky et al. (2006), Michel et al. (2006), and Cady et al. (2004) found 
duration to be one of the most important distinguishers of migraine, the other aforementioned 
studies did not have these same findings. This disparity in findings is most likely due to the 
difference in comparison groups among the studies. Studies by Wang et al. (2008) and Martin et 
al. (2005) indicated that their migraine samples included probable migraineurs, while the meta-
analysis by Smetana (2000) likely also included probable migraineurs (although it was unclear 
from the methods). As noted earlier, younger probable migraineurs often endorse shorter-than-
typical headache duration (i.e., under 4 hours), and thus may mitigate the importance of duration 
in differentiating migraine from non-migraine headache. This rationale is strengthened by the 
present finding that duration showed poor sensitivity when including probable migraineurs (27% 
vs. 100% without probable migraineurs).  
 Another notable difference between this study and others is the lack of predictive 
importance of disability within the current study. Studies that found disability to be an important 
predictor of migraine, such as those by Wang et al. (2008), Cady et al. (2004), and Lipton et al. 
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(2003), were inconsistent in how disability was defined, and therefore, their findings regarding 
the utility of this variable cannot be directly compared. In addition, these studies were conducted 
with treatment-seeking samples that are overall more likely to endorse a greater level of 
disability, while the current study was conducted using a comparison group of individuals having 
numerous forms of primary and secondary headaches and thus varying levels of disability.  
Implications of the current findings 
 The OOP of the current 4-question screener was a positive endorsement on 3 or more 
items, showing 94% sensitivity and 92% specificity. The current screener outperformed the ID 
MigraineTM (81% sensitivity, 75% specificity; Lipton et al., 2003), the 3-item screener developed 
by Cady et al., 2004 (77% sensitivity), the screener recommended by Pryse-Phillips et al. (2002) 
(86% sensitivity and 73% specificity), and even a longer measure, the MS-Q (92% sensitivity 
and 81% specificity; Lainez et al., 2005). The screener also performed well among probable 
migraineurs, showing a sensitivity of 98% and specificity of 75% at its OOP (positively 
endorsing at least 2 out of 4 items). Although the current screener appears to be extremely 
accurate at differentiating migraine from other headache and may be especially useful clinically, 
screeners are often best used among the population in which they are developed until further 
validation assesses their utility in other populations. 
 The use of this screening measure within a non-treatment-seeking sample could help to 
identify individuals with migraine who have not previously been diagnosed by a healthcare 
professional. Early diagnosis is essential to adequate treatment for migraine (Lipton et al., 1994) 
and early diagnostic screening is one of the best ways to reduce societal burden and cost, as well 
as individual burden, disability, and chronification of headache over time (Dowson et al., 2002; 
Lipton & Silberstein, 2001; Lipton et al., 2002, 2004; Solomon, 1997; Stewart et al., 1996; Von 
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Korff et al., 1998). This screener may prove to be useful in differential diagnosis for individuals 
with multiple headache types (Stang & VonKorff, 1994) and could help to identify those at risk 
for other comorbidities (Lipton et al., 2004), although these possibilities await empirical 
verification.  
Limitations and Future Directions 
 Some limitations of the current study and screener exist. One main limitation is that the 
authors did not re-administer independently to the holdout sample the 4 items that comprised the 
screening measure. Although there is not yet any evidence to suggest that symptom endorsement 
would differ if the screening measure was administered in isolation (versus with other items), the 
possibility exists and awaits empirical confirmation. In addition, as mentioned above, headache 
sufferers in the current study were diagnosed using a computerized questionnaire, which does not 
allow for inquiry or clarification of responses, as does an in-person interview. Future research 
should attempt to validate this screening measure in this same population by administering the 
screener and comparing results to gold standard diagnosis as assigned by in-person diagnostic 
interviews. 
 Future research should also attempt to validate this measure within a treatment-seeking 
sample. Preliminary findings suggest that this measure could be extremely useful in 
differentiating migraine from other headaches in non-treatment-seeking young adults; however, 
the use of this screener does not have to be limited to this population. Further attempts to validate 
this screening measure in other samples could expand its usefulness to clinical populations. 
Because physicians often do not have time to assess all diagnostic criteria or conduct a lengthy 
structured interview (Martin et al., 2005), the inclusion of this 4-item measure could be used to 
identify a large proportion of migraineurs that are often not diagnosed (Lipton et al., 2002; Stang 
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& VonKorff, 1994). In addition to clinical uses, the screener could also be used in research 
studies to more accurately estimate the prevalence rate of migraine in a given population. 
Finally, head-to-head comparisons of this screener and other widely used migraine screening 
measures are warranted. Collectively, this study and future validation efforts will clarify the 
potential utility of this promising screener. 
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Table 1 
Demographics and Headache Diagnoses 
 
 Experimental 
Sample 
n = 887 
Validation 
Sample 
n = 942 
P = Entire 
Sample 
N = 1,829 
Demographics     
          Age M (SD) 19.05 (1.96) 19.12 (2.13) .476 19.09 (2.05) 
Gender   .511  
          Female 628 (70.8%) 680 (72.2%)  1,308 (71.5%) 
          Male 259 (29.2%) 262 (27.8%)  521 (28.5%) 
Race   .877  
          White 661 (74.5%) 699 (74.2%)  1,360 (74.4%) 
          Black 147 (16.6%) 184 (19.5%)  331 (18.1%) 
          Other 79 (8.9%) 59 (6.3%)  138 (7.5%) 
Headache Type     
   CM 23 (2.6%) 18 (1.9%) .325 41 (2.2%) 
   EM w/out aura 29 (3.3%) 45 (4.8%) .102 74 (4.0%) 
   EM w/aura 17 (1.9%) 26 (2.8%) .234 43 (2.4%) 
   Migraine 69 (7.8%) 89 (9.4%) .137 158 (8.6%) 
   *PM *266 (30.0%) *301 (32.0%) *.364 *567 (31.0%) 
  CTTH 12 (1.4%) 16 (1.7%) .547 28 (1.5%) 
  ETTH 184 (20.7%) 177 (18.8%) .294 361 (19.7%) 
  PTTH 219 (24.7%) 203 (21.5%) .111 422 (23.1%) 
  Cluster 18 (2.0%) 18 (1.9%) .855 36 (2.0%) 
  Posttraumatic 40 (4.5%) 52 (5.5%) .323 92 (5.0%) 
  MOH 1 (0.1%) 1 (0.1%) .966 2 (0.1%) 
  No Diagnosis 78 (8.8%) 85 (9.0%) .863 163 (8.9%) 
  Non-Migraine 552 (62.2%) 552 (58.6%) .137 1,104 (60.4%) 
CM = Chronic migraine; EM = Episodic migraine; PM = Probable migraine; CTTH = Chronic 
tension-type headache; ETTH = Episodic tension-type headache; PTTH = Probable tension-type 
headache; MOH = Medication overuse headache 
 
*Probable migraineurs were excluded from the preliminary analyses, but were included as part of 
the migraine group in secondary analyses 
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Table 2 
Mean Headache Days Per Month (0-30) 
 
Headache Type Experimental 
Sample 
n = 887 
Validation 
Sample 
n = 942 
P = Entire Sample 
N = 1,829 
   CM 18.61 (SD = 4.07) 18.44 (4.66) .905 18.54 (4.28) 
   EM w/out aura 7.76 (5.60) 6.29 (3.28) .159 6.86 (4.37) 
   EM w/aura 6.94 (3.09) 6.65 (3.43) .782 6.77 (3.27) 
   PM 7.27 (5.53) 7.38 (5.90) .831 7.33 (5.72) 
  CTTH 16.67 (3.26) 18.94 (5.54) .218 17.96 (4.77) 
  ETTH 4.91 (3.41) 4.85 (2.91) .844 4.88 (3.17) 
  PTTH 5.03 (4.76) 5.16 (4.17) .766 5.09 (4.48) 
  Cluster  9.67 (5.25) 8.78 (5.02) .607 9.22 (5.08) 
  Posttraumatic 7.53 (5.47) 8.13 (6.46) .633 7.87 (6.03) 
  *MOH 17 25 NA 21 (5.66) 
  No Diagnosis 2.83 (3.00) 2.34 (1.80) .207 2.57 (2.45) 
CM = Chronic migraine; EM = Episodic migraine; PM = Probable migraine; CTTH = Chronic 
tension-type headache; ETTH = Episodic tension-type headache; PTTH = Probable tension-type 
headache; MOH = Medication overuse headache 
 
*MOH sufferers could not be compared on average headache days per month because there were 
only two MOH sufferers. 
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Table 3 
Mean Headache Severity (0-10) 
 
Headache Type Experimental 
Sample 
n = 887 
Validation 
Sample 
n = 942 
P = Entire Sample 
N = 1,829 
   CM M = 6.13 (SD = 1.06) 6.78 (1.35) .093 6.41 (1.22) 
   EM w/out aura 6.48 (1.77) 5.73 (1.76) .079 6.03 (1.79) 
   EM w/aura 6.18 (1.29) 6.42 (1.39) .562 6.33 (1.34) 
   PM 5.24 (1.60) 5.15 (1.65) .540 5.19 (1.63) 
  CTTH 5.33 (1.23) 4.44 (1.21) .065 4.82 (1.28) 
  ETTH 4.01 (1.43) 3.88 (1.28) .366 3.95 (1.36) 
  PTTH 3.67 (1.47) 3.68 (1.49) .909 3.67 (1.48) 
  Cluster 5.28 (1.99) 5.50 (1.82) .729 5.39 (1.89) 
  Posttraumatic 5.10 (1.85) 5.12 (1.87) .969 5.11 (1.85) 
  MOH 5 9 NA 7 (2.83) 
  No Diagnosis 3.00 (1.60) 2.65 (1.50) .148 2.82 (1.55) 
CM = Chronic migraine; EM = Episodic migraine; PM = Probable migraine; CTTH = Chronic 
tension-type headache; ETTH = Episodic tension-type headache; PTTH = Probable tension-type 
headache; MOH = Medication overuse headache 
 
*MOH sufferers could not be compared on average headache severity because there were only 
two MOH sufferers. 
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Table 4 
 
Experimental Sample: 2X2 Symptom Tables for Each Migraine Symptom (n = 621 with 
headache) 
 
 
 
  Migraine (excluding PM) 
  Yes No 
Duration (4-72 hours) Present 69 42 
 Not Present 0 510 
 Total 69 552 
    
Unilateral Present 34 211 
 Not Present 35 339 
 Total 69 550 
    
Pulsing Present 55 279 
 Not Present 14 272 
 Total 69 551 
    
Severity ≥ 5 Present 63 194 
 Not Present 6 358 
 Total 69 552 
    
Worsened by activity Present 53 180 
 Not Present 15 372 
 Total 69 552 
    
Nausea Present 45 61 
 Not Present 24 491 
 Total 69 552 
    
Vomiting Present 13 11 
 Not Present 56 539 
 Total 69 550 
    
Photophobia Present 62 180 
 Not Present 7 363 
 Total 69 543 
    
Phonophobia Present 62 246 
 Not Present 7 306 
 Total 69 552 
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Disability Present 44 65 
 Not Present 25 482 
 Total 69 547 
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Table 5 
 
Experimental Sample: Migraine Symptom Performance  
 
 
 
 Sensitivity  Specificity  +LR -LR PPV NPV AUC  
Duration (4-
72 hrs) 
100% 
(95% CI: 
95-100) 
92% 
(90-94%) 
13.14 
(9.83-
17.58) 
 62% 
(52-
71%) 
100% 
(99-
100%) 
96% 
(95-
98%) 
Unilateral 49%  
(37-62%) 
62%  
(57-66%) 
1.28 
(.99-
1.67) 
.82 
(.65-
1.05) 
14% 
(10-
19%) 
91% 
(87-
93%) 
56% 
(49-
63%) 
Pulsing 80%  
(68-88%) 
49%  
(45-54%) 
1.57 
(1.36-
1.82) 
.41 
(.26-
.66) 
16% 
(13-
21%) 
95% 
(92-
97%) 
65% 
(58-
71%) 
Severity ≥ 5 91%  
(82-97%) 
65%  
(61-69%) 
2.60 
(2.27-
2.97) 
0.13 
(.06-
.29) 
25% 
(19-
30%) 
98% 
(96-
99%) 
78% 
(73-
83%) 
Worsened by 
activity 
78%  
(66-87%) 
67%  
(63-71%) 
2.39 
(2.01-
2.85) 
.33 
(.21-
.51) 
23% 
(18-
29%) 
96% 
(94-
98%) 
72% 
(66-
79%) 
Nausea 65%  
(53-76%) 
89%  
(86-91%) 
5.90 
(4.40-
7.91) 
.39 
(.28-
.54) 
42% 
(33-
52%) 
95% 
(93-
97%) 
77% 
(70-
84%) 
Vomiting 19%  
(11-30%) 
98%  
(96-99%) 
9.42 
(4.39-
20.20) 
.83 
(.74-
.93) 
54% 
(33-
74%) 
91% 
(88-
93%) 
58% 
(50-
66%) 
Photophobia 90%  
(80-96%) 
67%  
(63-71%) 
2.71 
(2.35-
3.13) 
0.15 
(.08-
.31) 
26% 
(20-
32%) 
98% 
(96-
99%) 
78% 
(73-
83%) 
Phonophobia 90%  
(80-96%) 
55%  
(51-60%) 
2.02 
(1.78-
2.28) 
.18 
(.09-
.37) 
20% 
(16-
25%) 
98% 
(95-
99%) 
72% 
(67-
78) 
Disability 64%  
(51-75%) 
88%  
(85-91%) 
5.37 
(4.02-
7.17) 
.41 
(.30-
.56) 
40% 
(31-
50%) 
95% 
(93-
97%) 
76% 
(69-
83) 
CI = Confidence Interval; Prevalence = 11%  
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Table 6 
 
Experimental Sample: 2X2 Symptom Tables for Each Migraine Symptom (including probable 
migraineurs) (n = 887 with headache) 
 
 
 
  Migraine (including PM) 
  Yes No 
Duration (4-72 hours) Present 91 42 
 Not Present 242 510 
 Total 333 552 
    
Unilateral Present 179 211 
 Not Present 155 339 
 Total 334 550 
    
Pulsing Present 256 279 
 Not Present 78 272 
 Total 334 551 
    
Severity ≥ 5 Present 246 194 
 Not Present 89 358 
 Total 335 552 
    
Worsened by activity Present 222 180 
 Not Present 112 372 
 Total 334 552 
    
Nausea Present 167 61 
 Not Present 168 491 
 Total 335 552 
    
Vomiting Present 30 11 
 Not Present 304 539 
 Total 334 550 
    
Photophobia Present 302 180 
 Not Present 33 363 
 Total 335 543 
    
Phonophobia Present 296 246 
 Not Present 38 306 
 Total 334 552 
    
	   50	  
Disability Present 131 65 
 Not Present 204 482 
 Total 335 547 
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Table 7 
 
Experimental Sample: Migraine Symptom Performance (including probable migraineurs) 
 
 
 
 Sensitivity Specificity  +LR -LR PPV NPV AUC  
Duration (4-
72 hrs) 
27% (95% 
CI: 23-32) 
92%  
(90-94%) 
3.59 
(2.56-
5.04) 
.79 
(.73-
.84) 
68% 
(60-
76%) 
68% 
(64-
71%) 
60% 
(56-
64%) 
Unilateral 54%  
(48-59%) 
62%  
(57-66%) 
1.40 
(1.21-
1.62) 
0.75 
(.66-
.86) 
46% 
(41-
51%) 
69% 
(64-
73%) 
58% 
(54-
62%) 
Pulsing 77%  
(72-81%) 
49%  
(45-54%) 
1.51 
(1.37-
1.68) 
0.47 
(.38-
.58) 
48% 
(44-
52%) 
78% 
(73-
82%) 
63% 
(60-
67%) 
Severity ≥ 5 73%  
(68-78%) 
65%  
(61-69%) 
2.09 
(1.83-
2.38) 
.41 
(.34-
.49) 
56% 
(51-
61%) 
80% 
(76-
84%) 
69% 
(66-
73%) 
Worsened by 
activity 
66%  
(61-72%) 
67%  
(63-71%) 
2.04 
(1.77-
2.35) 
0.50 
(.42-
.58) 
55% 
(50-
60%) 
77% 
(73-
81%) 
67% 
(63-
71%) 
Nausea 50%  
(44-55%) 
89%  
(86-91%) 
4.51 
(3.48-
5.85) 
.56 
(.50-
.63) 
73% 
(67-
79%) 
75% 
(71-
78%) 
70% 
(65-
73%) 
Vomiting 9%  
(6-13%) 
98%  
(96-99%) 
4.49 
(2.28-
8.84) 
.93 
(.90-
.96) 
73% 
(57-
86%) 
64% 
(61-
67%) 
53% 
(49-
57%) 
Photophobia 90%  
(86-93%) 
67%  
(63-71%) 
2.72 
(2.40-
3.08) 
0.15 
(.11-
.20) 
63% 
(58-
67%) 
92% 
(89-
94%) 
78% 
(75-
81%) 
Phonophobia 89%  
(85-92%) 
55%  
(51-60%) 
1.99 
(1.80-
2.20) 
.21 
(.15-
.28) 
55% 
(50-
59%) 
89% 
(85-
92%) 
72% 
(68-
75%) 
Disability 39%  
(34-45%) 
88%  
(85-91%) 
3.29 
(2.53-
4.29) 
.69 
(.63-
.76) 
69% 
(60-
73%) 
70% 
(67-
74%) 
63% 
(59-
67%) 
CI = Confidence Interval; Prevalence = approximately 37%  
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Table 8 
Validation Sample: 2X2 Tables of Screener at Different Cut-off Points 
 
 
 
  Migraine (excluding PM) 
  Yes No  
1 or more symptoms Positive screen 87 329 
 Negative screen 0 209 
 Total 87 538 
    
2 or more symptoms Positive screen 87 136 
 Negative screen 0 402 
 Total 87 538 
    
3 or more symptoms Positive screen 82 41 
 Negative screen 5 497 
 Total 87 538 
    
All 4 symptoms Positive screen 50 5 
 Negative screen 37 533 
 Total 87 538 
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Table 9 
Validation Sample: Screener Performance at Different Cut-off Points 
 
  
 
 Sensitivity  Specificity +LR -LR PPV NPV AUC 
1 or 
more 
100% (95% 
CI: 96-100) 
39%  
(35-43%) 
1.64 
(1.53-
1.75) 
 21% 
(17-
25%) 
100% 
(98-
100%) 
69% 
(65-
74%) 
2 or 
more 
100%  
(96-100%) 
75%  
(71-78%) 
3.96 
(3.42-
4.57) 
 39% 
(33-
46%) 
100% 
(99-
100%) 
87% 
(85-
90%) 
3 or 
more 
94%  
(87-98%) 
92%  
(90-94%) 
12.37 
(9.17-
16.67) 
.06 
(.03-
.15) 
67% 
(58-
75%) 
99% 
(98-
100%) 
93% 
(90-
96%) 
All 4 57%  
(46-68%) 
99%  
(98-100% 
61.84 
(25.37-
150.73) 
.43 
(.34-
.55) 
91% 
(80-
97%) 
94% 
(91-
95%) 
78% 
(72-
85%) 
Disease prevalence = 13%
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Table 10 
Validation Sample: 2X2 Tables of Screener at Different Cut-off Points (including probable 
migraineurs) 
 
 
 
  Migraine (including PM) 
  Yes No  
1 or more symptoms Positive screen 384 329 
 Negative screen 0 209 
 Total 384 538 
    
2 or more symptoms Positive screen 378 136 
 Negative screen 6 402 
 Total 384 538 
    
3 or more symptoms Positive screen 197 41 
 Negative screen 187 497 
 Total 384 538 
    
All 4 symptoms Positive screen 61 5 
 Negative screen 323 533 
 Total 384 538 
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Table 11 
Validation Sample: Screener Performance at Different Cut-off Points (including probable 
migraineurs) 
 
 
 
 Sensitivity  Specificity +LR -LR PPV NPV AUC 
1 or 
more 
100% (95% 
CI: 99-100) 
39%  
(35-43%) 
1.64 
(1.53-
1.75) 
 54% 
(50-
58%) 
100% 
(98-
100%) 
69% 
(66-
73%) 
2 or 
more 
98%  
(97-99%) 
75%  
(71-78%) 
3.89 
(3.37-
4.51) 
.02 
(.01-
.05) 
74% 
(70-
77%) 
99% 
(97-
99%) 
87% 
(84-
89%) 
3 or 
more 
51%  
(46-56%) 
92%  
(90-94%) 
6.73 
(4.94-
9.18) 
.53 
(.47-
.59) 
83% 
(77-
87%) 
73% 
(69-
76%) 
72% 
(68-
75%) 
All 4 16%  
(12-20%) 
99%  
(98-100% 
17.09 
(6.93-
42.14) 
.85 
(.81-
.89) 
92% 
(83-
97%) 
62% 
(59-
66%) 
58% 
(54-
61%) 
Disease prevalence = 42% 
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Table 12 
Performance of Screener Among Genders 
 
 1 or more 2 or more 3 or more All 4 
Men     
     - screen 77 137 220 248 
     + screen 178 118 35 7 
  AUC 72% (95% CI: 
62-83) 
89% (84-94%) 94% (84-100%) 70% (51-89%) 
     
Women     
     - screen 132 271 464 608 
     + screen 535 396 203 59 
  AUC  68% (63-74%) 86% (83-90%) 93% (89-96%) 80% (73-87%) 
     
Chi Square 11.395 12.824 26.896 10.330 
P =  =.001 <.001 <.001 =.001 
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Table 13 
Performance of Screener Among Races 
 
 1 or more 2 or more 3 or more All 4 
White     
     - screen 157 300 502 634 
     + screen 529 386 184 52 
     AUC 70% (95% CI: 
64-75) 
87% (84-91%) 93% (89-97%) 81% (73-89%) 
     
Other     
     - screen 52 108 182 222 
     + screen 184 128 54 14 
     AUC 68% (59-78%) 87% (82-93%) 95% (90-100%) 72% (59-85%) 
     
Chi Square .073 .294 1.424 .718 
P =  .787 .588 .233 .397 
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APPENDIX B: MIGRAINE DIAGNOSTIC CRITERIA 
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1. G43  Migraine 
1.1 G43.0  Migraine without aura 
 A. At least 5 attacks fulfilling criteria B–D 
 B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated) 
 C. Headache has at least 2 of the following characteristics: 
  1. unilateral location 
  2. pulsating quality 
  3. moderate or severe pain intensity 
  4. aggravation by or causing avoidance of routine physical activity (e.g., walking  
  or climbing stairs) 
 D. During headache at least 1 of the following: 
  1. nausea and/or vomiting 
  2. photophobia and phonophobia 
 E. Not attributed to another disorder 
1.2. G 43.10 Typical aura with migraine headache 
 A. At least two attacks fulfilling criteria B-D 
 B. Aura consisting of at least one of the following, but no motor weakness: 
 1. Fully reversible visual symptoms including positive features (e.g. flickering 
 lights, spots or lines) and/or negative features (i.e. loss of vision) 
 2. Fully reversible sensory symptoms including positive features (i.e. pins and 
 needles) and/or negative features (i.e. numbness) 
 3. Fully reversible dysphasic speech disturbance 
 C. At least two of the following: 
 1. Homonymous visual symptoms and/or unilateral sensory symptoms 
 2. At least one aura symptom develops gradually over ≥5 minutes and/or 
 different aura symptoms occur in succession over ≥5 minutes 
 3. Each symptom lasts ≥5 minutes and ≥60 minutes 
 D. Headache fulfilling criteria B-D for 1.1 Migraine without aura begins during the aura 
 or follows the aura within 60 minutes 
 E. Symptoms not attributed to another disorder
	   60	  
 
 
 
 
 
 
 
 
 
 
 
APPENDIX C: SDIH-R 
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Included are 10 migraine diagnostic questions (marked with *), a question of headache 
frequency, two questions assessing for aura symptoms, five questions to assess for other 
headaches (posttraumatic, cluster, and medication overuse [MOH]), and a question regarding 
disability. 
 
1. Do you ever get headaches? 
 a. Yes  b. No 
 
2. On average, how many DAYS PER MONTH do you have a headache? (PLEASE ENTER A 
NUMBER BETWEEN 0-30) 
 _____ days 
 
*3. If 0 is no pain, 5 is moderate pain, and 10 is the worst pain imaginable, what is the average 
pain intensity of these headaches? (pick one number between 0 and 10) 
 _____ 
 
*4. If left untreated or unsuccessfully treated, about long would these headaches usually last? 
 a. Less than 30 minutes   
b. At least 30 minutes but less than 2 hours  
c. At least 2 hours but less than 4 hours  
d. Between 4 hours and 3 days  
e. Between 3 days and 7 days 
f. Longer than 7 straight days   
  
5. For approximately how long have you been having these headaches? 
 a. Less than 3 months 
 b. 3 months 
 c. 4 months or more  
 
*6. How many of these headaches have you had in your life? 
 a. Less than 5 
 b. 5 – 9 
 c. 10 – 20 
 d. More than 20 
 
*7. Which of the following best describes your pain? 
 a. Pulsating/Throbbing b. Tight pressure (non-pulsating) 
 
*8. Is the pain typically experienced on one side or both sides of your head? 
 a. Typically one side  b. Typically both sides 
 
*9. Is the pain made worse by routine physical activities or cause you to avoid routine physical 
activities (like walking, bending over, or climbing stairs)?  
 a. Yes  b. No 
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*10. Do you often feel nauseous or sick to your stomach during these headaches? 
 a. Yes  b. No 
 
*11. Do you often vomit or throw up during these headaches? 
 a. Yes  b. No 
 
*12. Are you often sensitive to light during these headaches? 
 a. Yes  b. No 
 
*13. Are you often sensitive to sound during these headaches? 
 a. Yes  b. No 
 
14. Do you often experience any symptoms shortly before the headache pain actually begins, 
such as changes in your vision (blurry vision, seeing spots or zigzag lines), changes in your 
sensation (numbness, tingling), or changes in your speech? 
 a. Yes 
 b. No  
 
15. How many times have you experienced these symptoms (i.e., blurry vision, seeing spots or 
zigzag lines) before having a headache? 
 a. 1 
 b. 2 – 5 
 c. 6 – 10 
 d. More than 10 
 
16. Do you use any medications to treat these headaches? 
 a. Yes 
 b. No 
 
17. If you use medication, how many days per week do you use any type of medication to treat 
your headaches? 
 a. Less than 1 day per week 
 b. 1-2 days per week 
 c. 3 days per week 
 d. 4 or more days per week 
 
18. How long have you been using these medications at this frequency? 
 a. 3 months or less 
 b. More than 3 months 
 
19. Did your headache develop or get worse when you started using these medications at this 
frequency? 
 a. Yes 
 b. No 
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20. Did this headache develop shortly after a head injury or head trauma? 
 a. Yes 
 b. No 
 
21. Have you ever been diagnosed with cluster headaches? 
 a. Yes 
 b. No 
 
22. Do these headaches interfere with your work, school, or personal life? 
 a. Yes 
 b. No 
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APPENDIX D: 4-ITEM SCREENING MEASURE 
	   65	  
1. If left untreated or unsuccessfully treated, about long would these headaches usually last? 
a. Less than 30 minutes   
b. At least 30 minutes but less than 2 hours  
c. At least 2 hours but less than 4 hours  
d. Between 4 hours and 3 days  
e. Between 3 days and 7 days 
f. Longer than 7 straight days   
 
2. Do you often feel nauseous or sick to your stomach during your headaches? 
a. a. Yes  b. No 
 
3. Are you often sensitive to light during your headaches? 
a. a. Yes  b. No 
 
4. Are you often sensitive to sound during your headaches? 
a. a. Yes  b. No 
 
 
 
*An answer of “d” on question 1 indicates migraine while all other responses indicate non-
migraine headache. 
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